Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization: Findings From the ASSESS-AKI and ARID Studies
Coca SG, Vasquez-Rios G, Mansour SG, Moledina DG, Thiessen-Philbrook H, Wurfel MM, Bhatraju P, Himmelfarb J, Siew E, Garg AX, Hsu CY, Liu KD, Kimmel PL, Chinchilli VM, Kaufman JS, Wilson M, Banks RE, Packington R, McCole E, Kurth MJ, Richardson C, Go AS, Selby NM, Parikh CR. Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization: Findings From the ASSESS-AKI and ARID Studies. American Journal Of Kidney Diseases 2022, 81: 190-200. PMID: 36108888, PMCID: PMC9868060, DOI: 10.1053/j.ajkd.2022.08.007.Peer-Reviewed Original ResearchConceptsSoluble tumor necrosis factor receptor 1Acute kidney injuryHeart failureClinical eventsIndex hospitalizationPlasma soluble tumour necrosis factor receptor 1Soluble tumour necrosis factor receptor concentrationsBiomarker measurementsKidney disease incidenceBaseline serum samplesKidney disease progressionLate heart failureTumor necrosis factor receptor 1Association of biomarkersProportional hazards modelNecrosis factor receptor 1Magnitude of associationFactor receptor 1AKI statusIndex admissionKidney eventsKidney outcomesAKI definitionKidney injuryHospital discharge